Tag
Moderna and Merck announced the success of their mRNA cancer vaccine in a Phase 3 melanoma trial, which could establish a new personalized treatment paradigm for cancer.
Moderna and Merck announced positive Phase 3 results for their personalized cancer vaccine, which reduced melanoma recurrence, causing Moderna stock to surge by over 110%.
Moderna's mRNA flu vaccine mFLUSIVA received FDA approval for adults over 50, marking the first mRNA-based flu shot. However, uncertainty remains due to the CDC advisory panel being defunct amid litigation, affecting coverage recommendations.
Moderna announced FDA approval of mFLUSIVA (mRNA-1010), a seasonal influenza vaccine for adults 50 and older, following unanimous advisory committee recommendations.
FDA advisors voted unanimously to approve Moderna's seasonal mRNA flu vaccine, mRNA-1010, after initial rejection by a Trump appointee. The vaccine showed 27% better efficacy than standard flu shot and stronger immune response than high-dose vaccine in older adults.
Moderna received $50 million from CEPI to develop an mRNA Ebola vaccine targeting the Bundibugyo strain, amid a severe outbreak in DRC with over 1,000 cases and 241 deaths.